Table of Contents
- How ICH Organizes Its Guidelines
- At a Glance: 2026 by Category
- Efficacy (E-Series): What Changed in 2026
- Multidisciplinary (M-Series): What Changed in 2026
- Quality (Q-Series): What's Still in Progress
- Safety (S-Series): A Quieter Year
- The eCTD v4.0 Backdrop Tying It All Together
- Why an Uneven Year Still Matters for Regulatory Teams
- How Kivo Supports ICH-Aligned Submissions
- FAQ
- Sources
What changed across ICH's Quality, Safety, Efficacy, and Multidisciplinary guideline categories in 2026? Efficacy and Multidisciplinary saw the year's real movement — a new E6(R3) annex on decentralized trials, a first-of-its-kind model-informed drug development guideline, and a new clinical protocol template all reached Step 4. Quality's big stability-testing revision is still in consultation, and Safety had no comparable milestone this cycle. The four categories don't move in lockstep, and 2026 is a clear example of that.
How ICH Organizes Its Guidelines
The International Council for Harmonisation sorts its guidelines into four categories, each with its own letter prefix: Quality (chemistry, manufacturing, stability), Safety (nonclinical pharmacology and toxicology), Efficacy (clinical trial design and conduct), and Multidisciplinary (topics that cut across the other three, such as electronic submission standards and terminology). Every guideline moves through the same five-step ICH process: Step 1 is expert working group consensus on a draft; Step 2 is Assembly endorsement and release for public consultation; Step 3 is review of consultation comments; Step 4 is final Assembly adoption of the harmonised text; Step 5 is implementation by each ICH region's own regulators, on each region's own timeline. "ICH adopted" and "ICH is in force everywhere" are not the same claim — Step 4 is a harmonised recommendation, not a binding rule, until a region's regulator (FDA, EMA, PMDA, and the rest) separately implements it. For the full category breakdown and guideline list, see Kivo's own Overview of ICH Guidelines; this piece picks up where that one leaves off, tracking what specifically moved in 2026.
At a Glance: 2026 by Category
Two categories reached a Step 4 milestone in 2026, one is mid-consultation, and one had no comparable milestone at all. This table lines up the year's flagship item per category before the section-by-section detail below.
| Category | Flagship 2026 Item | Furthest Step Reached in 2026 | Date |
|---|---|---|---|
| Efficacy (E) | E6(R3) Annex 2 — decentralized/RWD trials | Step 4 (final adoption) | June 3, 2026 |
| Efficacy (E) | E2D(R1) — post-approval safety reporting | Step 4 (reached late 2025; EU implementation in 2026) | EU effective March 18, 2026 |
| Multidisciplinary (M) | M15 — model-informed drug development | Step 4 (final adoption) | January 29, 2026 |
| Multidisciplinary (M) | M4Q(R2) — CTD Quality module revision | Step 2/3 (consultation under review) | Comments posted mid-February 2026 |
| Quality (Q) | Q1 — stability testing consolidation | Step 2 (released for consultation in 2025, still open) | Released April 11, 2025 |
| Safety (S) | No 2026 milestone identified | — (most recent major adoption: S12, Step 4) | S12 adopted March 2023 |
M11, the harmonised protocol template, isn't in this table because it was adopted for implementation in November 2025, not 2026 — it's covered below because its regional rollout and practical relevance are still very much a 2026 story.
Efficacy (E-Series): What Changed in 2026
Efficacy had the most consequential year of any category. Two separate guidelines reached Step 4 in 2026, and both touch how trials are run and how safety data gets reported afterward.
E6(R3) Annex 2 — decentralized and real-world-data trials. The main E6(R3) Good Clinical Practice rewrite (its Principles & Objectives document plus Annex 1, covering traditional interventional trials) reached Step 4 back on January 6, 2025, replacing E6(R2)'s prescriptive, one-size-fits-all structure with a risk-proportionate, quality-by-design approach built around identifying each trial's own "critical to quality" factors[1]. Annex 2 is the sequel: it reached Step 4 on June 3, 2026, and specifically addresses pragmatic clinical trials, decentralized clinical trials, and trials incorporating real-world data sources — designs the original E6(R2) text was never written to accommodate[1]. The EU adopted Annex 2 on June 25, 2026, with an effective date of January 15, 2027[1]; Canada's Principles and Annex 1 took effect April 1, 2026, with full compliance required from October 1, 2026[1].
E2D(R1) — post-approval safety reporting. E2D(R1) reached Step 4 on September 15, 2025, updating the 2003-era rules for how post-approval individual case safety reports (ICSRs) get defined, categorized, and reported[2]. The revision's most concrete addition is a new section on digital platforms as safety-data sources — social media, mobile health apps, patient support programs, and similar "organized data collection systems" that simply didn't exist as reporting channels when the original E2D was written[2], plus explicit guidance on handling safety data from non-interventional studies[3]. The expedited-ICSR reporting clock itself — 15 calendar days from day zero — carries over unchanged[2]. The EU's implementation date for E2D(R1) is March 18, 2026[3].
Multidisciplinary (M-Series): What Changed in 2026
The Multidisciplinary category — the guidelines that cut across Quality, Safety, and Efficacy rather than sitting inside one of them — was the year's other major source of movement.
M15 — model-informed drug development. M15 reached Step 4 on January 29, 2026, after release for public consultation on November 6, 2024[4]. It's ICH's first general framework for model-informed drug development (MIDD) — the use of computational modeling and simulation, spanning population PK/PD, physiologically based pharmacokinetic (PBPK) modeling, exposure-response analysis, quantitative systems pharmacology, and AI/ML methods, to generate evidence that supports a regulatory decision[4]. Rather than prescribing specific models, it establishes a harmonised assessment framework — Context of Use, Model Risk, Model Impact, Consequence of a Wrong Decision — and a standard Model Analysis Plan/Model Analysis Report structure meant to be read alongside topic-specific guidelines like E9, E11, M12, and M13[4].
M11 — the harmonised clinical trial protocol template. M11 (formally the Clinical Electronic Structured Harmonised Protocol, or CeSHarP) was adopted for implementation on November 19, 2025[5]. It bundles three linked documents — a guideline on protocol design principles, a standard protocol template, and a technical specification for exchanging protocol data electronically — aimed squarely at the absence of any globally harmonised protocol format[5]. It's described as a foundational piece of ICH's broader electronic-standards (ESTRI) work, and it applies across all ICH regions and all trial phases and therapeutic areas[5].
M4Q(R2) — still mid-process. Not every Multidisciplinary item finished in 2026. M4Q(R2), which revises the Common Technical Document's Quality module (Modules 2.3 and 3.2), is still working through the ICH process: a public-consultation comment summary was posted to EMA's site in mid-February 2026, and as of this writing the guideline sits in Step 2, with those comments now under Step 3 review[6]. No Step 4 date has been set.
Quality (Q-Series): What's Still in Progress
Quality's headline 2026 story is similar: real work, but not yet a finished guideline. The Q1 revision — consolidating the current Q1A(R2) through Q1E stability-testing guidelines into a single, modernized document — reached Step 2 and was released for consultation on April 11, 2025[7]. As of this writing, Q1 remains in that consultation phase, with no confirmed Step 3 sign-off or Step 4 adoption date. Worth flagging directly: Kivo could not confirm a Step 3 or Step 4 milestone for Q1 at the time this post was researched — if that changes, this post should be updated rather than left implying the older status.
Safety (S-Series): A Quieter Year
Here's the honest answer, not a padded one: Kivo's research for this post did not turn up a Safety-series guideline that reached a major ICH process milestone in 2026. The most recent major Safety-series adoption remains S12 (nonclinical biodistribution considerations for gene therapy products), which reached Step 4 back in March 2023[8] — three years before this post, not a 2026 event. That's not evidence Safety work has stalled; ICH's working groups run on their own internal timelines; a category can go a year or more between Step 4 milestones while earlier-stage work (Step 1 or Step 2) continues out of public view. It's simply a real asymmetry worth naming rather than glossing over: 2026 was an Efficacy-and-Multidisciplinary year, not an every-category year.
The eCTD v4.0 Backdrop Tying It All Together
One piece of Multidisciplinary infrastructure sits underneath every guideline above: the format every submission actually gets filed in. eCTD v4.0's regional rollout kept shifting through 2026 — FDA has accepted v4.0 since September 2024; Japan's PMDA made it mandatory in April 2026; EMA has accepted it optionally since December 2025, "strongly recommended" from Q1 2027 and mandatory from Q1 2028; FDA's own mandatory cutover isn't until 2029. For the fuller timeline against each agency's review-speed data, see Kivo's FDA, EMA, PMDA & More: Global Drug Approval Timelines Compared. Every guideline above — from E6(R3)'s new trial designs to M15's modeling evidence to M11's structured protocols — eventually travels through this same filing infrastructure, on a timeline that varies by region independently of when the guideline itself was adopted.
Why an Uneven Year Still Matters for Regulatory Teams
The takeaway isn't to track every category equally — it's that 2026 exposure depends on what a team actually files. Decentralized or pragmatic-trial sponsors have new obligations under E6(R3) Annex 2. Teams using PK/PD or exposure-response modeling now have a harmonised framework (M15) to document that evidence against, where none existed before January 2026. And any NDA, BLA, or MAA filer (see Kivo's NDA vs. BLA vs. MAA comparison) files in the same ICH CTD format regardless of which category moved this year — a format itself mid-transition to eCTD v4.0 on a region-by-region schedule unrelated to the Q1 or M4Q(R2) timelines. Treating "ICH guidelines" as one undifferentiated thing updating on a predictable cycle is the real mistake; the four categories run on four separate paces, and 2026 made that unusually visible.
How Kivo Supports ICH-Aligned Submissions
Kivo's Regulatory Information Management (RIM) module is built around the same harmonised structure these guidelines define: 450+ pre-formatted ICH templates, pre-built submission structures aligned to agency guidelines, and a module-by-module copy function for building a new submission from an existing one, all linked back to source documents in Kivo's DMS. RIM's submission-type support spans INDs, CTAs, BLAs, NDAs, IDMPs, ANDAs, and CTIS filings, and its template library specifically includes ICH M11 clinical protocol templates alongside FDA, Health Canada, and EU M1/IMPD formats — a direct tie to the M11 template discussed above, available the same way for a US IND or an EU CTA. For how Kivo structures the broader submission-management workflow, including the eCTD Viewer that accepts eCTD 4.0 sequences across eight jurisdictions (FDA, EMA, PMDA, Health Canada, Swissmedic, TGA, HSA, and MFDS), see Kivo's RIM Explained: Regulatory Information Management & Systems; for one specific application type running through this same infrastructure, see Kivo's IND Application Guide or NDA Application Guide.
Kivo's compliance posture is explicitly aligned to the International Council for Harmonisation, alongside FDA 21 CFR Part 11, EU Annex 11, ISO 27001, Good Clinical Practice, and the TMF Reference Model — and designed to align with the FDA's Computer Software Assurance (CSA) guidance, a risk-based framework that, like several of the 2026 guidelines above, reflects regulators moving toward proportionate oversight rather than uniform prescriptive rules. Document control for any ICH-governed submission runs on the same DMS core as Kivo's eTMF and QMS modules, with native, Part 11-compliant e-signature included standard at no added charge. Over 200 sponsor, consultant, and CRO teams run on Kivo's platform today.
FAQ
What are the four ICH guideline categories?
Quality (Q), covering chemistry, manufacturing, and stability; Safety (S), covering nonclinical pharmacology and toxicology; Efficacy (E), covering clinical trial design and conduct; and Multidisciplinary (M), covering cross-cutting topics like electronic submission standards and terminology that don't fit neatly into the other three.
What is ICH E2D(R1) and what does it cover?
E2D(R1) updates the definitions and reporting standards for post-approval individual case safety reports, reaching Step 4 on September 15, 2025. Its main addition is guidance on digital platforms — social media, health apps, patient support programs — as post-approval safety-data sources that didn't exist when the original 2003 guideline was written.
What is changing with eCTD v4.0, and when is it mandatory?
eCTD v4.0 is a new electronic submission format rolling out on different timelines per region: mandatory in Japan since April 2026, optional in the EU since December 2025 (mandatory Q1 2028), and not mandatory in the US until 2029, though the FDA has accepted v4.0 filings since September 2024.
What is ICH M11, and why does it matter for clinical trial protocols?
M11 is ICH's harmonised clinical trial protocol template (CeSHarP) — a standard protocol design guideline, table-of-contents template, and technical specification for electronic data exchange, adopted for implementation November 19, 2025. It matters because no globally harmonised protocol format existed before it, meaning every sponsor and region effectively used its own structure.
Does ICH update all four guideline categories every year?
No. 2026 is a clear example: Efficacy and Multidisciplinary each had a guideline reach Step 4, Quality's major revision (Q1) remained in consultation, and no Safety-series guideline reached a comparable milestone. Each category's working groups run on independent timelines.
Sources
- CASRAI. "ICH E6(R3): What Changed in Good Clinical Practice" — E6(R3) Principles/Annex 1 Step 4 date (January 6, 2025), Annex 2 Step 4 date (June 3, 2026), EU and Canada implementation dates.
- RAPS (Regulatory Focus), Joanne S. Eglovitch, "ICH Adopts E2D(R1) Guideline on Post-Approval Safety Data Management" — E2D(R1) Step 4 date (September 15, 2025) and guideline content.
- ECA Academy. "ICH E2D(R1) Guideline on Safety Data Management Reaches Step 4" — EU implementation date (March 18, 2026) and non-interventional-study provisions.
- ICH. M15, "General Principles for Model-Informed Drug Development," Step 4 Final Guideline (January 29, 2026) — scope, framework, and Step 2 consultation date (November 6, 2024).
- ICH. "M11 Explainer" (May 2026) — CeSHarP components, scope, and adoption-for-implementation date (November 19, 2025).
- ECA Academy / EMA. "ICH M4Q(R2): List of Comments Published" — Step 2/Step 3 status and EMA comment-summary timing (mid-February 2026).
- ICH. M4Q(R2)/Q1 working documents, database.ich.org — Q1 Step 2 draft guideline release date (April 11, 2025).
- ICH. S12, "Nonclinical Biodistribution Considerations for Gene Therapy Products," Step 4 Guideline (March 2023) — most recent major Safety-series adoption as of this writing.

